Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...
Faults in a certain part of the immune system might be at the root of some long covid cases, new research suggests. For many people, covid is an illness that blusters in and out of our lives as cases ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback